

### REMARKS

Applicants traverse the restriction requirement and request reconsideration. With the amendment to claim 42, all methods now define a method for treating diseases mediated by p38 and are linked by a common inventive concept. Claims 1 and 34 were examined previously and were allowed. No basis has been given as to why the various diseases need to be separately searched. There is no indication that the groups defined in the restriction requirement are separately classified or that diseases mediated by p38 cannot be searched simultaneously.


To provide a complete response, Applicants select Group I, drawn to a method of treating Rheumatoid Arthritis.

Applicants also traverse the requirement to elect compounds of formula I having a specific definition for "B". The full scope of compounds of formula I were searched and examined previously. The amendments made with the Request for Continued Examination were not intended to present new subject matter to examine. Claim 42 erroneously recited a method for treating cancerous cell growth mediated by raf kinase. This error has been corrected. It was the intention of the amendments to correct minor errors in the claims, to claim sub-generic species with greater particularity and to replace the cancelled claims.

To comply with the requirement, Applicants elect species wherein "B" is phenyl.

No fee is believed to be due with this response, however, the Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Richard J. Traverso, Reg. No. 30,595  
Attorney/Agent for Applicant(s)

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1, Suite 1400  
2200 Clarendon Boulevard  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410  
Attorney Docket No.: BAYER-0011-C01

Date: December 4, 2003